ELATE
Research type
Research Study
Full title
Evaluating the role of IL-17 as an orchestrator of peripheral-central cross talk in depressive symptoms
IRAS ID
345892
Contact name
Jonathan Cavanagh
Contact email
Sponsor organisation
NHS GG&C
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
50 PsD patients with active disease for whom anti-IL17 treatment is indicated as part of standard clinical care, in line with NICE/SMC treatment guidance. The decision to prescribe anti-IL-17 treatment for active PsD will be made by the patients’ usual clinical team in advance, and independently, of the study. Consenting eligible
participants will be randomized 1:1 to either immediately receive (fast tracked) secukinumab, bimekizumab or Ixekizumab sc per normal dose loading regime for
six weeks, or a placebo. After the treatment period, placebo recipients
will receive IL17.
All participants will undergo multi-modal neuroimaging before
randomisation and again after the six week randomised treatment
period. The duration of placebo exposure is justified on the basis that it
is consistent with current local routine screening and waiting times
to start biologics from treatment decision.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
25/YH/0039
Date of REC Opinion
27 Mar 2025
REC opinion
Further Information Favourable Opinion